19 November 2024
Physiomics plc
("Physiomics" or "the Company")
Result of AGM
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company's offices in Oxford, were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.
Details of the proxy voting results are shown in the table below.
| Ordinary Resolutions | Votes For | % | Votes Against | % | Votes Withheld | Votes Total | % of ISC Voted |
| 1. Approval of the accounts | 13,702,827 | 98.48% | 210,852 | 1.52% | 5,844 | 13,919,523 | 6.8% |
| 2. Re-appointment of Dr Peter Sargent as a Director of the Company | 12,408,973 | 97.73% | 287,661 | 2.27% | 1,222,889 | 13,919,523 | 6.8% |
| 3. Re-election of Dr Shalabh Kumar as a Director of the Company | 12,408,973 | 97.73% | 287,661 | 2.27% | 1,222,889 | 13,919,523 | 6.8% |
| 4. Appointment and renumeration of auditor | 13,697,496 | 98.45% | 216,183 | 1.55% | 5,844 | 13,919,523 | 6.8% |
| 5. Authority to allot shares | 13,328,063 | 95.79% | 585,616 | 4.21% | 5,844 | 13,919,523 | 6.8% |
| Special Resolution | | | | | | | |
| 6. Disapplication of shareholders' statutory pre-emption rights | 12,108,403 | 87.03% | 1,805,276 | 12.97% | 5,844 | 13,919,523 | 6.8% |
ISC - Issued Share Capital
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.